Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.

[1]  U. Reddy,et al.  Prediction and prevention of recurrent stillbirth. , 2007, Obstetrics and gynecology.

[2]  Gordon C. S. Smith,et al.  Maternal and biochemical predictors of antepartum stillbirth among nulliparous women in relation to gestational age of fetal death , 2007, BJOG : an international journal of obstetrics and gynaecology.

[3]  F. Malone,et al.  Pregnancy Loss Rates After Midtrimester Amniocentesis , 2006, Obstetrics and gynecology.

[4]  K. Nicolaides,et al.  First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death , 2006, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[5]  U. Reddy,et al.  Maternal age and the risk of stillbirth throughout pregnancy in the United States. , 2006, American journal of obstetrics and gynecology.

[6]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, The New England journal of medicine.

[7]  F. Malone,et al.  Quad Screen as a Predictor of Adverse Pregnancy Outcome , 2005, Obstetrics and gynecology.

[8]  F. Malone,et al.  First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). , 2004, American journal of obstetrics and gynecology.

[9]  J. Simpson,et al.  Pregnancy-Associated Plasma Protein A, Free β-hCG, Nuchal Translucency, and Risk of Pregnancy Loss , 2004, Obstetrics and gynecology.

[10]  L. Dodds,et al.  Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. , 2003, American journal of obstetrics and gynecology.

[11]  A. Orr-Urtreger,et al.  Decreased first trimester PAPP‐A is a predictor of adverse pregnancy outcome , 2002, Prenatal diagnosis.

[12]  Gordon C. S. Smith,et al.  Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  M. Melbye,et al.  Second‐Trimester Maternal Serum Alpha‐Fetoprotein and Risk of Adverse Pregnancy Outcome , 2001, Obstetrics and gynecology.

[14]  K. Nicolaides,et al.  First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications , 2000, BJOG : an international journal of obstetrics and gynaecology.

[15]  K. Spencer.  Second‐trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome , 2000, Prenatal diagnosis.

[16]  Y Yaron,et al.  Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. , 1999, American journal of obstetrics and gynecology.

[17]  L. Boots,et al.  Elevated second-trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. , 1994, American journal of obstetrics and gynecology.

[18]  D. Kanon,et al.  Fetal crown-rump length: reevaluation of relation to menstrual age (5-18 weeks) with high-resolution real-time US. , 1992, Radiology.